SCHEMBL4465102

SCHEMBL4465102

CN=Nc1ccccc1N=NC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
ALDH1A1 P00352 1/20 0.35
TSHR P16473 3/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ACHE P22303 2/20 0.32
ALPL P05186 1/20 0.30
ALPI P09923 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14253086 0.83 TSHR (0.52) NPC1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL12324597 0.83 TSHR (0.52) NPC1SMN1; SMN2MEN1KMT2ALMNA
SCHEMBL14260674 0.81 MAPT (0.71) NPC1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL14366502 0.81 L3MBTL1 (0.71) NPC1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL14001568 0.81 MAPT (0.71) NPC1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL16141030 0.81 MAPT (0.71) NPC1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL14020317 0.79 MEN1 (0.48) NPC1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL12870014 0.77 ALDH1A1 (0.50) MEN1KMT2ALMNAL3MBTL1KDM4E
SCHEMBL13283105 0.77 KDM4E (0.41) NPC1SMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL14253085 0.77 KMT2A (0.53) NPC1RAB9AMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3015555-B1 METHOD FOR AMPLIFYING NUCLEIC ACID SYSMEX CORP (JP) 2017-12-20 EP claimed
EP-2090304-A2 Use of sugar phosphates, sugar phosphate analogues, amino acids and/or amino acid analogues for modulating the glycose-enzyme complex, the malate aspartate shuttle and/or transaminases ScheBo Biotech AG (DE) 2009-08-19 EP disclosed
EP-1368018-A2 USE OF SUGAR PHOSPHATE, SUGAR PHOSPHATE ANALOGUES, AMINO ACIDS AND/OR AMINO ACID ANALOGUES FOR MODULATING THE GLYCOLYSIS-ENZYME COMPLEX, THE MALATE-ASPARTATE SHUTTLE AND/OR TRANSAMINASES Schebo Biotech AG (DE) 2003-12-10 EP disclosed
WO-2002072077-A2 USE OF AMINO ACIDS, AMINO ACID ANALOGUES, SUGAR PHOSPHATES AND SUGAR PHOSPHATE ANALOGUES FOR TREATMENT OF TUMORS, TREATMENT OF SEPSIS AND IMMUNOSUPPRESSION SCHEBO BIOTECH AG (DE) 2002-09-19 WO disclosed
EP-0138750-B1 PROCESS FOR THE PRODUCTION OF SUBSTITUTED BENZIMIDAZOLES CIBA-GEIGY AG (CH) 1987-09-09 EP disclosed
EP-0138750-A1 Process for the production of substituted benzimidazoles CIBA-GEIGY AG (CH) 1985-04-24 EP disclosed